Concretely, ALKBH5 acts as an oncogene in glioblastoma (Zhang et al., 2017), acute myeloid leukemia (Shen et al., 2020), breast cancer (Zhang et al., 2016), and ovarian carcinoma (Jiang et al., 2020), while functioning as a tumor suppressor in lung cancer (Zhang et al., 2021), hepatocellular carcinoma (Chen et al., 2020), and osteosarcoma (Yuan et al., 2021). This evidence concerns the gene ALKBH5 and acute myeloid leukemia.